List of Myfembree drug patents

Myfembree is owned by Myovant Sciences.

Myfembree contains Estradiol; Norethindrone Acetate; Relugolix.

Myfembree has a total of 4 drug patents out of which 0 drug patents have expired.

Myfembree was authorised for market use on 26 May, 2021.

Myfembree is available in tablet;oral dosage forms.

Myfembree can be used as management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women.

Drug patent challenges can be filed against Myfembree from 2024-12-18.

The generics of Myfembree are possible to be released after 29 September, 2037.

MYFEMBREE's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7300935 MYOVANT SCIENCES Thienopyrimidine compounds and use thereof
Jan, 2024

(10 months from now)

US8058280 MYOVANT SCIENCES Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof
Jan, 2024

(10 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9346822 MYOVANT SCIENCES Thienopyrimidine compounds and use thereof
Feb, 2024

(10 months from now)

US11033551 MYOVANT SCIENCES Methods of treating uterine fibroids
Sep, 2037

(14 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 18, 2025
New Product (NP) May 26, 2024
New Indication (I) Aug 5, 2025

Drugs and Companies using ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX ingredient

NCE-1 date: 2024-12-18

Market Authorisation Date: 26 May, 2021

Treatment: Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women

Dosage: TABLET;ORAL

More Information on Dosage

MYFEMBREE family patents

20

United States

8

Japan

8

European Union

5

Australia

4

China

4

Canada

4

Israel

3

Brazil

3

New Zealand

3

Argentina

3

Mexico

3

Morocco

3

EA

2

Portugal

2

Spain

2

Norway

2

Lithuania

2

Slovenia

2

Hungary

2

Poland

2

Denmark

1

Moldova, Republic of

1

Russia

1

Croatia

1

Colombia

1

Taiwan, Province of China

1

Korea, Republic of

1

Hong Kong

1

South Africa

1

Cyprus

1

RS

1

Netherlands

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in